Expression of vitamin D receptor and metabolizing enzymes in multiple sclerosis-affected brain tissue.

Vitamin D deficiency has been implicated as a risk factor for multiple sclerosis (MS), but how vitamin D metabolism affects MS pathophysiology is not understood. We studied the expression of vitamin D receptor (VDR) and related enzymes, including 1,25(OH)(2)D-24-hydroxylase (24-OHase; CYP24A1) and 25(OH)D-1α-hydroxylase (CYP27B1), in CNS tissues of 39 MS patients and 20 controls and in primary human glial cells in vitro. In control and MS normal-appearing white matter (NAWM), nuclear VDR immunostaining was observed in oligodendrocyte-like cells, human leukocyte antigen (HLA)-positive microglia, and glial fibrillary acidic protein-positive astrocytes. There was a 2-fold increase in VDR transcripts in MS NAWM versus control white matter (p = 0.03). In chronic active MS lesions, HLA-positive microglia/macrophages showed nuclear VDR staining; astrocytes showed nuclear and cytoplasmic VDR staining. Staining for 24-OHase was restricted to astrocytes.VDR and CYP27B1 mRNA expressions were increased in active MS lesions versus NAWM (p < 0.01, p = 0.04, respectively). In primary human astrocytes in vitro, the active form of vitamin D, 1,25(OH)(2)D(3), induced upregulation of VDR and CYP24A1. Tumor necrosis factor and interferon-γ upregulated CYP27B1 mRNA in primary human microglia and astrocytes. Increased VDR expression in MS NAWM and inflammatory cytokine-induced amplified expression of VDR and CYP27B1 in chronic active MS lesions suggest increased sensitivity to vitamin D in NAWM and a possible endogenous role for vitamin D metabolism in the suppression of active MS lesions.

[1]  K. Schuurman,et al.  Phenotyping primary human microglia: Tight regulation of LPS responsiveness , 2012, Glia.

[2]  M. Filippi,et al.  A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon β-1b in patients with multiple sclerosis , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[3]  S. Mellgren,et al.  Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial , 2012, Multiple sclerosis.

[4]  F. Barkhof,et al.  Efficacy of vitamin D3 as add-on therapy in patients with relapsing–remitting multiple sclerosis receiving subcutaneous interferon beta-1a: A Phase II, multicenter, double-blind, randomized, placebo-controlled trial , 2011, Journal of the Neurological Sciences.

[5]  T. Holmøy,et al.  Vitamin D in the healthy and inflamed central nervous system: access and function , 2011, Journal of the Neurological Sciences.

[6]  M. Stein,et al.  A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis , 2011, Neurology.

[7]  Simon C. Potter,et al.  Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis , 2011, Nature.

[8]  T. Dwyer,et al.  Higher 25‐hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis , 2010, Annals of neurology.

[9]  D. Melzer,et al.  Vitamin D and risk of cognitive decline in elderly persons. , 2010, Archives of internal medicine.

[10]  P. Knekt,et al.  Serum vitamin D and the risk of Parkinson disease. , 2010, Archives of neurology.

[11]  J. Souberbielle,et al.  Is hypovitaminosis D one of the environmental risk factors for multiple sclerosis? , 2010, Brain : a journal of neurology.

[12]  J. M. Burton,et al.  A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis , 2010, Neurology.

[13]  E. Mowry,et al.  Vitamin D status is associated with relapse rate in pediatric‐onset multiple sclerosis , 2010, Annals of neurology.

[14]  D. Eyles,et al.  Vitamin D, a neuro-immunomodulator: Implications for neurodegenerative and autoimmune diseases , 2009, Psychoneuroendocrinology.

[15]  M. Holick,et al.  25-Hydroxyvitamin D in cerebrospinal fluid during relapse and remission of multiple sclerosis , 2009, Multiple sclerosis.

[16]  P. Menheere,et al.  Vitamin D Status Is Positively Correlated with Regulatory T Cell Function in Patients with Multiple Sclerosis , 2009, PloS one.

[17]  A. Kessels,et al.  Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis , 2008, Multiple sclerosis.

[18]  L. Bö,et al.  Downregulation of macrophage inhibitory molecules in multiple sclerosis lesions , 2007, Annals of neurology.

[19]  Hans Lassmann,et al.  The Immunopathology of Multiple Sclerosis: An Overview , 2007, Brain pathology.

[20]  T. Dwyer,et al.  Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia , 2007, Journal of Neurology.

[21]  A. Ascherio,et al.  Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. , 2006, JAMA.

[22]  M. Rehli,et al.  Monocyte-derived cells express CYP27A1 and convert vitamin D3 into its active metabolite. , 2006, Biochemical and biophysical research communications.

[23]  P. Lips.  Vitamin D physiology. , 2006, Progress in biophysics and molecular biology.

[24]  J. Adams,et al.  Toll-Like Receptor Triggering of a Vitamin D-Mediated Human Antimicrobial Response , 2006, Science.

[25]  K. Spach,et al.  Vitamin D3 Confers Protection from Autoimmune Encephalomyelitis Only in Female Mice1 , 2005, The Journal of Immunology.

[26]  J. McGrath,et al.  Distribution of the Vitamin D receptor and 1α-hydroxylase in human brain , 2005, Journal of Chemical Neuroanatomy.

[27]  Glenville Jones,et al.  Enzymes involved in the activation and inactivation of vitamin D. , 2004, Trends in biochemical sciences.

[28]  Jean-Paul Noben,et al.  Proteomic analysis of cerebrospinal fluid from multiple sclerosis patients , 2004, Proteomics.

[29]  D. Eyles,et al.  1,25-Dihydroxyvitamin D3 induces nerve growth factor, promotes neurite outgrowth and inhibits mitosis in embryonic rat hippocampal neurons , 2003, Neuroscience Letters.

[30]  C. Montero-Menei,et al.  Vitamin D3 inhibits proinflammatory cytokines and nitric oxide production by the EOC13 microglial cell line , 2003, Journal of neuroscience research.

[31]  P. Brachet,et al.  Treatment of experimental autoimmune encephalomyelitis in rat by 1,25-dihydroxyvitamin D3 leads to early effects within the central nervous system , 2003, Acta Neuropathologica.

[32]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[33]  J. Fyfe,et al.  Cubilin dysfunction causes abnormal metabolism of the steroid hormone 25(OH) vitamin D3 , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[34]  A. Howie,et al.  Extrarenal Expression of 25-Hydroxyvitamin D3-1α-Hydroxylase1 , 2001 .

[35]  P. Valk,et al.  Staging of multiple sclerosis (MS) lesions: pathology of the time frame of MS. , 2000 .

[36]  Henrik Vorum,et al.  An Endocytic Pathway Essential for Renal Uptake and Activation of the Steroid 25-(OH) Vitamin D3 , 1999, Cell.

[37]  T. Veenstra,et al.  Distribution of 1,25-dihydroxyvitamin D3 receptor immunoreactivity in the rat brain and spinal cord , 1999, Journal of Chemical Neuroanatomy.

[38]  S. Brimijoin,et al.  1,25-Dihydroxyvitamin D3 receptors in the central nervous system of the rat embryo , 1998, Brain Research.

[39]  A. Dusso,et al.  ␥-interferon-induced Resistance to 1,25-(oh) 2 D 3 in Human Monocytes and Macrophages: a Mechanism for the Hypercalcemia of Various Granulomatoses* , 2022 .

[40]  P. Brachet,et al.  Differential expression of M‐CSF, LIF, and TNF‐α genes in normal and malignant rat glial cells: Regulation by lipopolysaccharide and vitamin D , 1996, Journal of neuroscience research.

[41]  P. Brachet,et al.  1,25‐Dihydroxyvitamin D3 regulates NT‐3, NT‐4 but not BDNF mRNA in astrocytes , 1994, Neuroreport.

[42]  P. Brachet,et al.  1,25-dihydroxyvitamin D3 regulates the synthesis of nerve growth factor in primary cultures of glial cells. , 1994, Brain research. Molecular brain research.

[43]  I. Stamenkovic,et al.  Organ distribution in rats of two members of the low-density lipoprotein receptor gene family, gp330 and LRP/alpha 2MR, and the receptor-associated protein (RAP). , 1994, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[44]  P. Brachet,et al.  Expression of 25(OH) vitamin D3 24-hydroxylase gene in glial cells. , 1993, Neuroreport.

[45]  J. Delmez,et al.  Extrarenal production of calcitriol. , 1990, Kidney international. Supplement.

[46]  M. Haussler,et al.  Immunocytochemical detection of 1,25-dihydroxyvitamin D receptors in normal human tissues , 1988 .

[47]  S. Manolagas,et al.  1,25-dihydroxyvitamin D3 receptors in human leukocytes. , 1983, Science.